COMP <GO>
SHC vs MRK // OPTIONS IMPLIED MOVE & PUT/CALL SKEW
Sotera Health Company (NASDAQ) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: SHC 3
— MRK 12
▲ OPTIONS IMPLIED MOVE & PUT/CALL SKEW LEADER: MRK
LAST: $18.15 (-2.94%) • MKT CAP: $5.34B
options-implied-move
7.20%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
options-implied-move
6.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SHC VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SHC | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 55.50% | 74.80% | -19.30 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.10% | 20.70% | -17.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | 33.5x | 15.3x | +18.20 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.80% | 3.42% | -0.62 | MRK | /fcf-yield <GO> |
| Operating Margin | 8.20% | 34.30% | -26.10 | MRK | /operating-margins <GO> |
| Net Profit Margin | 6.70% | 28.10% | -21.40 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | 1.30% | +4.40 | SHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.56 | 5.19 | -3.63 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | SHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew ACTIVE | 7.20% | 6.60% | +0.60 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 47.9 | 56.9 | -8.92 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.10 | 0.92 | +0.18 | SHC | /macro-sensitivity <GO> |
| Forward P/E Multiple | 63.7x | 18.4x | +45.30 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.34B | $361.02B | -$355.68B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SHC REV | MRK REV | SHC GROSS % | MRK GROSS % | SHC FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.16B | $65.01B | 55.5% | 74.8% | $149.2M | $12.36B |
| FY 2024 | $1.10B | $64.17B | 54.7% | 76.3% | $45.1M | $18.10B |
| FY 2023 | $1.05B | $60.12B | 44.0% | 44.0% | -$194.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SHC // BETA 1.10
MRK // BETA 0.92